RHB-104

RedHill Awaits Patent for RHB-104, Potential MS Treatment, from Japan

RedHill BiopharmaĀ recentlyĀ announcedĀ that it hasĀ received a Notice of Allowance from theĀ Japan Patent Office for a new patent coveringĀ RHB-104 as a potentialĀ treatment of multiple sclerosis (MS).Ā Once granted, the patent will be valid until 2032. The European Patent Office also recently approvedĀ a patent application for the drug with this…

Phase 2 Study of Oral Antibiotic to Treat Relapsing MS, RHB-104, Nearing Finish

RedHill Biopharma announced that theĀ final patient has completed the last step of itsĀ Phase 2 clinical study (CEASE-MS) of RHB-104 as a potential treatment forĀ people with relapsing-remitting multiple sclerosis (RRMS). RHB-104 is an antibiotic oral medication that blocks inflammation in addition to killing bacteria. RHB-104 was originally developedĀ as a treatment for…

Experimental MS Oral Antibiotic Combination Therapy Showing Promise in Phase 2a Study, RedHill Biopharma Reports

RedHill Biopharma, Ltd.Ā recently announced promising interim results from itsĀ ongoing CEASE-MS Phase 2a clinical trial evaluating the safety and efficacy of a fixed dose of RHB-104 as an add-onĀ therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). RHB-104 consists of an oral capsule formulation of an antibiotic combination therapy ā€”…

RedHill’s Experimental MS Therapy, RHB-104, Receives Notice of Allowance on U.S. Patent

RedHill Biopharma, Ltd., an Israeli biopharmaceutical company focused on the development and commercialization of oral-administered small-molecule medicines for the treatment of inflammatory and gastrointestinal diseases, recently announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering its…

RRMS Clinical Study of New Antibiotic Therapy Nearing End

RedHill Biopharma, Ltd., recently announced the conclusion of the last dosing and patient follow-up visit for its Phase 2a proof-of-concept study to assess the efficacy and safety of the experimental drug RHB-104 as an add-on therapy to interferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS).